A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors

Breast Cancer Research and Treatment

Volumn 136, Issue 2, 2012, Pages 479-486

  Lavigne, Jill E ^a   Heckler, Charles ^b   Mathews, Jennifer L ^a   Palesh, Oxana ^c   Kirshner, Jeffrey J ^b   Lord, Raymond ^b   Jacobs, Andrew ^b   Amos, Eric ^a   Morrow, Gary R ^b   Mustian, Karen ^b  

^a ST JOHN FISHER COLLEGE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti epileptics; Anxiety; Breast; Cancer; Cancer survivorship; Gabapentin; Neurontin; Randomized controlled trial

Indexed keywords

BENZODIAZEPINE; GABAPENTIN; PLACEBO;

ADULT; ANALYSIS OF COVARIANCE; ANXIETY DISORDER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVOR; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SPEILBERGER STRAIT TRAIT ANXIETY INVENTORY; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME;

AMINES; ANTI-ANXIETY AGENTS; ANXIETY; BREAST NEOPLASMS; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MIDDLE AGED; SURVIVORS; TREATMENT OUTCOME;

EID: 84868213452     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2251-x     Document Type: Article

References (33)

1. Chalasani P, Downey L, Stopeck AT (2010) Caring for the breast cancer survivor: A guide for primary care physicians. Am J Med 123(6):489-495
2. Khatcheressian J, Wolff A, Smith T et al (2006) American Society of Clinical Oncology 2006 update of breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24(31):5091-5097
3. Lavigne JE, Griggs JJ, Tu XM, Lerner DJ. Hot flashes, fatigue, treatment exposures and work productivity in breast cancer survivors. J Cancer Surviv. 2008 Dec;2(4):296-302
4. Hartl K, Schennach R, Muller M, Engel J, Reinecker H, Sommer H, Friese K (2010) Quality of life, anxiety, and oncological factors: A follow-up study of breast cancer patients. Psychosomatics 51:112-123
5. Vahdaninia M, Omidvari S, Montazeri A (2010) What do predict anxiety and depression in breast cancer patients? A follow-up study. Soc Psychiatry Psychiatr Epidemiol 45(3):355-361
6. Armes J, Crowe M, Colbourne L et al (2009) Patients' supportive care needs beyond the end of cancer treatment: A prospective, longitudinal survey. J Clin Oncol 27(36):6172-6179
7. Kroenke K, Spitzer RL, Williams JBW, Monahan PO, Lowe B (2007) Anxiety disorders in primary care: Prevalence, impairment, comorbidity and detection. Ann Intern Med 146:317-325
8. Ravindran LN, Stein MB (2010) The pharmacologic treatment of anxiety disorders: A review of progress. J Clin Psychiatry 71:7
9. Pande AC, Feltner DE, Jefferson JW et al (2004) Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: A placebocontrolled multi-center study. J Clin Psychopharmacol 24: 141-149
10. Montgomery SA, Tobias K, Zornberg GL et al (2006) Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: A 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67:771-782
11. Scheiner FR (2006) Clinical practice: Social anxiety disorder. N Engl J Med 355:1029-1036
12. Landmark CJ (2008) Antiepileptic drugs in non-epilepsy disorders: Relations between mechanisms of action and clinical efficacy. CNS Drugs 22(1):27-47
13. Jacox A, Carr DB, Payne R, et al. (1994) Management of cancer pain. Clinical practice guideline no. 9. AHCPR publication no. 94-0592. Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, Rockville
14. Keskinbora K, Pekel EF, Aydinli I (2007) Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: A randomized open trial. J Pain Symptom Manage 34:183-189
15. Caraceni A, Zecca E, Bonezzi C et al (2004) Gabapentin for neuropathic cancer pain: A randomized, controlled trial from the gabapentin cancer pain study group. J Clin Oncol 22:2909-2917
16. Caraceni A, Brunelli C, Martini C et al (2005) Cancer pain assessment in clinical trials. A review of the literature. J Pain Symptom Manage 29:507-519
17. Fassoulaki A, Triga A, Melemeni A et al (2005) Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer. Anesth Analg 101:1427-1432
18. Menigaux C, Adam F, Guignard B, Sessler DI, Chauvin M (2005) Preoperative gabapentin decreases anxiety and improves early functional recovery from knee surgery. Anesth Analg 100: 1394-1399
19. Caraceni A, Portenoy RK (1999) A working group of the IASP task force on cancer pain. An international survey of cancer pain characteristics and syndromes. Pain 82:263-274
20. Pandya KJ, Morrow GR, Roscoe JA et al (2005) Gabapentin for hot flashes in 420 women with breast cancer: A randomized double-blind placebo-controlled trial. Lancet 366:818-824
21. Speilberger CD, Gorsuch RL, Luschene R (1970) STAI manual for the state-trait anxiety inventory. Consulting Psychologists, Palo Alto
22. Beaver K, Tysver-Robinson D, Campbell M, Twomey M, Williamson S, Hindley A et al (2009) Comparing hospital and telephone follow-up after treatment for breast cancer: Randomized equivalence trial. BMJ 338:s3147
23. Van den Bergh R, Essink-Bot ML, Roobol MJ et al (2009) Anxiety and distress during active surveillance for early prostate cancer. Cancer 115(17):386-3878
24. Den Oudsten BL, Van Heck GL, Van der Steeg AFW, Roukema JA, DeVries J (2009) The WHOQOL-100 has good psychometric properties in breast cancer patients. J Clin Epidemiol 62(2): 195-205
25. Fenlon DR, Corner JL, Haviland J (2009) Menopausal hot flushes after breast cancer. Eur J Cancer Care 18(2):14-148
26. Cundy K, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, Barrett RW, Gallop MA (2004) XP13512: A novel gabapentin prodrug: II. Improved oral availability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 311:324-333
27. Laird B, Colvin L, Fallon M (2008) Management of cancer pain: Basic principles and neuropathic cancer pain. Eur J Cancer 48: 1078-1082
28. Gabapentin. DRUGDEX- System. Thomson Healthcare. http:// www.thomsonhc.com. Accessed 7 Aug 2012
29. Vaidya R, Sood R, Karlin N, Jatoi A (2011) Benzodiazepine use in breast cancer survivors: Findings from a consecutive series of 1000 patients. Oncology 81:9-11
30. Orriols L, Phillip P, Moore N et al (2011) Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther 89(4):595-601
31. Cole J, Kando J (1993) Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. J Clin Psychiatry 54:49-63
32. Lader M (1999) Limitations on the use of benzodiazepines in anxiety and insomnia: Are they justified? Eur Neuropsychopharmacol 9:s399-s940
33. Baldwin D, Woods R, Lawson R (2011) Efficacy of drug treatments for generalized anxiety disorder: Systemic review and meta-analysis. BMJ 342:d1199